Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma.

Biomedicines · 2024 · PMC11274263 · PMID 39062006

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In SARAH and SIRveNIB trials, the median OS in the TARE arms ranged from 8 to 14 months, compared to 9.9 to 11.4 months in the sorafenib arms, and did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.